Tag:
TriLipix
Latest Headlines
Latest Headlines
FDA: TriLipix may not cut patients' heart risks
The questions about Abbott Laboratories' cholesterol drug TriLipix aren't going away. The FDA issued a safety communication saying the drug may not lower a patient's risk of heart attack or stroke.
FDA panel favors Trilipix combo, but asks for trial
New questions about the efficacy of Abbott's Trilipix drug weren't strong enough to inspire a thumbs down from an FDA advisory panel. The agency's committee of experts recommended in a 9-to-4 vote
Abbott's Trilipix faces loss of combo indication
Another drug faces the loss of an FDA-approved use. This time, it's Trilipix, the Abbott Laboratories heart drug. And just like the proposed revocation of Avastin's indication for breast cancer use,
Krumholz questions Abbott blood-lipid drugs
Yale cardiologist Harlan Krumholz takes on the Abbott Laboratories lipid drugs TriLipix and TriCor in Forbes. Pointing to big growth in sales of the two drugs--28 percent year-over-year, to $372
AZ inks TriLipix deal with Abbott
Is AstraZeneca doing enough to combat its coming patent-cliff sales slump? Some analysts tell Bloomberg that the company looks increasingly desperate to fill that sales chasm--to the point that it
Abbott's TriCor follow-up gets FDA nod
Abbott shoots and it scores--finally. The FDA gave the OK to the company's TriLipix cholesterol drug, a follow-up to the highly successful TriCor, which is facing generic competition. The new med is
